Title:Anti-Amyloid-β Immunotherapy: A Leading Novel Avenue for Alzheimer's
Disease
Volume: 23
Issue: 1
Author(s): Parth Sharma, Ritchu Babbar*, Twinkle Sharma, Piyush Madaan, Sandeep Arora and Vishnu Nayak Badavath
Affiliation:
- Chitkara College of Pharmacy, Chitkara University, Punjab, India
Keywords:
Amyloid- β, cognitive impairment, dementia, immunotherapy, monoclonal antibody, neurodegeneration, tau protein.
Abstract: Alzheimer’s disease or senile dementia is principally acknowledged by the gradual accumulation
of neurotoxic amyloid- β protein in the brain and is considered as the initial event of
the phenomenon of this asymptomatic ailment. It prompts the decline in cognitive performance,
standard psychiatric functioning, and neuronal transmission across the brain. Significant inferences
were withdrawn by utilizing the recently introduced disease-modifying anti- amyloid- β
immunotherapy developed after performing the clinical and preclinical controlled trials to cure the
neurodegenerative malady. This strategy is worthwhile because of the clinical relevance and specific
targeted approach that exhibited the quenched immunotherapeutic effects and encouraged
clinical findings. In vitro fabricated, anti- amyloid- β recombinant monoclonal antibodies are passively
employed to promote clearance and antagonize the aggregation and synthesis of neurotoxic
and degenerative aggregates of amyloid-β. Thus, passive immunotherapy has an adequate impact
on treating this disorder, and currently, some other monoclonal pharmacological molecules are
under clinical trials to defeat this severe exacerbation with more efficacy and clinical benefits.
This review compendiously discusses the anti-amyloid-β immunotherapy, which will provide a
more proficient framework to be employed as a potential therapeutic approach.
